“…Neuroinflammation and its associated changes have been found in practically every neurodegenerative disorder ( Escartin et al, 2019 ). Many studies have linked neuroinflammation with epilepsy in human patients ( Ravizza et al, 2008 ; Aronica et al, 2012 ; Gibbons et al, 2013 ; Bedner et al, 2015 ; Ferrer, 2017 ; DeSena et al, 2018 ; Wenzel et al, 2019 ; Tan et al, 2021 ; Aulická et al, 2022 ), which has been replicated by a variety of animal epilepsy models including but not limited to: traumatic brain injury (TBI) associated epilepsy ( Abdul-Muneer et al, 2016 ; Kim et al, 2016 ; Webster et al, 2017 ; Sharma et al, 2019 ; Zhou et al, 2020 ; Gao et al, 2022 ; Golub and Reddy, 2022 ), post-ischemic stroke epilepsy ( Tröscher et al, 2021 ), glioma-associated epilepsy ( Olsen and Sontheimer, 2008 ; Buckingham et al, 2011 ; Buckingham and Robel, 2013 ; MacKenzie et al, 2016 ; Tewari et al, 2018 ; Campbell et al, 2020 ; Komiyama, 2022 ), kainic acid (KA)-induced epilepsy ( Canto et al, 2022 ; Han et al, 2019 ; Huang et al, 2022 ; Hubbard et al, 2016 ; McRae et al, 2010 ; Takahashi et al, 2010 ; Wolinski et al, 2022 ; Wu, Z et al, 2021 ), pilocarpine-induced epilepsy ( Borges et al, 2003 ; Canto et al, 2022 ; Han et al, 2019 ; Kong et al, 2012 ; Mátyás, A et al, 2021 ; Ravizza et al, 2008 ; Schauwecker, 2012 ; Shapiro et al, 2008 ; Wyeth et al, 2012 ), kindling models of epilepsy ( Kołosowska et al, 2016 ; Ueno et al, 2020 ), and a β1-integrin knockout astrogliosis mouse model ( Robel et al, 2015 ). The models particularly analogous to human MTLE-HS include the pilocarpine model and the KA model, which exhibit varying degrees of HS in addition to upregulation of proteins associated with immune responses and inflammation (…”